Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
The closing price of Skye Bioscience Inc (NASDAQ: SKYE) was $3.74 for the day, down -10.53% from the previous closing price of $4.18. In other words, the price has decreased by -$10.53 from its previous closing price. On the day, 1.74 million shares were traded. SKYE stock price reached its highest trading level at $4.206 during the session, while it also had its lowest trading level at $3.41.
Ratios:
Our analysis of SKYE’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 11.85 and its Current Ratio is at 11.85. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
On September 30, 2024, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $20.
On September 10, 2024, JMP Securities started tracking the stock assigning a Mkt Outperform rating and target price of $15.JMP Securities initiated its Mkt Outperform rating on September 10, 2024, with a $15 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Nov 18 ’24 when Diep Tuan Tu sold 19,489 shares for $4.99 per share. The transaction valued at 97,250 led to the insider holds 82,259 shares of the business.
Diep Tuan Tu sold 85 shares of SKYE for $472 on Nov 15 ’24. The Chief Development Officer now owns 101,748 shares after completing the transaction at $5.55 per share. On Nov 18 ’24, another insider, ARSENAULT KAITLYN, who serves as the Chief Financial Officer of the company, sold 43,206 shares for $4.99 each. As a result, the insider received 215,598 and left with 166,342 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SKYE now has a Market Capitalization of 115881656 and an Enterprise Value of 70702776.
Stock Price History:
The Beta on a monthly basis for SKYE is 1.96, which has changed by -0.4986595 over the last 52 weeks, in comparison to a change of 0.11937654 over the same period for the S&P500. Over the past 52 weeks, SKYE has reached a high of $8.26, while it has fallen to a 52-week low of $1.14. The 50-Day Moving Average of the stock is 64.32%, while the 200-Day Moving Average is calculated to be 20.02%.
Shares Statistics:
SKYE traded an average of 1.23M shares per day over the past three months and 3716260 shares per day over the past ten days. A total of 30.97M shares are outstanding, with a floating share count of 17.86M. Insiders hold about 42.35% of the company’s shares, while institutions hold 41.37% stake in the company. Shares short for SKYE as of 1749772800 were 2816636 with a Short Ratio of 2.29, compared to 1747267200 on 3212389. Therefore, it implies a Short% of Shares Outstanding of 2816636 and a Short% of Float of 13.66.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The performance of Skye Bioscience Inc (SKYE) in the stock market is under the watchful eye of 4.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is -$0.31, with high estimates of -$0.3 and low estimates of -$0.31.
Analysts are recommending an EPS of between -$0.98 and -$1.23 for the fiscal current year, implying an average EPS of -$1.14. EPS for the following year is -$1.38, with 6.0 analysts recommending between -$1.07 and -$1.69.
